Physician profile
Nathan Voise
NPI 1538471701
$1,722.83
in general payments reported to CMS, 2019-2025
14 companies · $13.76 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $308 · 2021: $541 · 2022: $431 · 2024: $63.52 · 2025: $13.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.52 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.52 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $646.57 | 2019-2024 | |
| Braintree Laboratories, INC. | $378.71 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.85 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $96.90 | 2021-2022 | |
| Pfizer INC. | $95.62 | 2021 | |
| Allergan, INC. | $70.67 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $56.60 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.67 | 2019-2025 | Eohilia |
| Janssen Biotech, INC. | $45.79 | 2022 | |
| Redhill Biopharma INC. | $42.11 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $31.10 | 2022 | |
| Medtronic, INC. | $20.06 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.04 | 2021 | |
| Intercept Pharmaceuticals, INC. | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Voise listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.